SiBone (NASDAQ:SIBN) Director Timothy Davis, Jr. Sells 3,780 Shares of Stock

SiBone (NASDAQ:SIBN) Director Timothy Davis, Jr. sold 3,780 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $14.47, for a total transaction of $54,696.60. Following the transaction, the director directly owned 69,222 shares in the company, valued at $1,001,642.34. This trade represents a 5.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

SiBone Trading Down 1.6%

Shares of SiBone stock opened at $13.87 on Tuesday. The firm has a market capitalization of $615.12 million, a PE ratio of -35.56 and a beta of 0.67. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34. The company’s fifty day moving average price is $13.55 and its two-hundred day moving average price is $16.03. SiBone has a 52-week low of $11.48 and a 52-week high of $21.89.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.07. The firm had revenue of $52.59 million for the quarter, compared to analyst estimates of $51.16 million. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. On average, analysts expect that SiBone will post -0.44 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SIBN. Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. TD Cowen dropped their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $18.00 price target (down from $20.00) on shares of SiBone in a research note on Tuesday, May 12th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, SiBone currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Hedge Funds Weigh In On SiBone

Several hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC boosted its holdings in shares of SiBone by 6.4% in the 1st quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock valued at $67,611,000 after buying an additional 320,286 shares during the last quarter. American Century Companies Inc. increased its position in SiBone by 22.5% during the 3rd quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock worth $41,777,000 after buying an additional 521,683 shares during the period. Vanguard Group Inc. increased its position in shares of SiBone by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock worth $49,331,000 after purchasing an additional 11,566 shares during the period. Granahan Investment Management LLC increased its position in shares of SiBone by 97.6% in the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after purchasing an additional 858,942 shares during the period. Finally, Nuveen LLC boosted its stake in SiBone by 5.1% in the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock valued at $28,041,000 after buying an additional 69,229 shares in the last quarter. 98.11% of the stock is owned by institutional investors.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.